Guidance for AAV Process Development Based on Cost Modeling

Time: 3:45 pm


  • Production of adeno-associated virus (AAV) and other viral vectors used for gene therapy faces challenges due to high manufacturing costs and compressed process development timelines compared to traditional biopharmaceuticals
  • Many process development activities may be undertaken to reduce manufacturing costs, but these costs are often not directly related to the process improvements being considered
  • In this work, process and cost models were built for AAV production and analyzed to assess the holistic impact of common process development objectives such as DNA digestion on the manufacturing costs
  • The insights from these analyses provide guidance for prioritization of various process development objectives